denkapparat Operations GmbH Takes Position in Exelixis, Inc. (NASDAQ:EXEL)

denkapparat Operations GmbH acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 21,410 shares of the biotechnology company's stock, valued at approximately $713,000. Exelixis makes up approximately 1.1% of denkapparat Operations GmbH's portfolio, making the stock its 20th largest holding.

A number of other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Exelixis by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after buying an additional 121,750 shares during the last quarter. Norges Bank acquired a new stake in Exelixis during the 4th quarter worth approximately $94,867,000. FMR LLC grew its holdings in Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock worth $63,891,000 after acquiring an additional 140,568 shares during the last quarter. Los Angeles Capital Management LLC increased its position in Exelixis by 20.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock valued at $71,828,000 after acquiring an additional 366,141 shares during the period. Finally, Two Sigma Advisers LP raised its stake in shares of Exelixis by 6.1% during the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company's stock valued at $44,182,000 after acquiring an additional 98,000 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on EXEL. Royal Bank of Canada upped their price target on Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Morgan Stanley raised Exelixis from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $30.00 to $40.00 in a research note on Monday, January 27th. Oppenheimer cut shares of Exelixis from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $41.00 to $33.00 in a research report on Friday, January 24th. BMO Capital Markets cut Exelixis from an "outperform" rating to a "market perform" rating and lifted their target price for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Exelixis in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Remove Ads

Exelixis Stock Performance

Shares of NASDAQ:EXEL traded down $0.30 during trading on Tuesday, reaching $36.62. 764,403 shares of the stock traded hands, compared to its average volume of 2,137,644. The stock has a market cap of $10.25 billion, a P/E ratio of 20.67, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The stock has a 50-day moving average of $35.72 and a two-hundred day moving average of $33.39. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity

In related news, EVP Patrick J. Haley sold 52,636 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bob Oliver sold 18,647 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the sale, the director now owns 33,514 shares of the company's stock, valued at approximately $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 in the last ninety days. Insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.